Xponance’s Alaunos Therapeutics TCRT Stock Holding History

Xponance’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-68	Closed	-$7K	–	1224
2022 Q1	$7K	Buy	+68	New	+$8.73K	﹤0.01%	1161
2021 Q3	–	Sell	-74	Closed	-$29K	–	1228
2021 Q2	$29K	Buy	+74	New	+$34.5K	﹤0.01%	1237

Other funds holding TCRT

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Xponance's TCRT Position: Q2 2022 in Review

Xponance sold out of Alaunos Therapeutics (TCRT) in Q2 2022, closing a stake of 68 shares — an estimated $7K sold.

Xponance first reported a position in TCRT in Q2 2021 and held it in 2 quarters. The position peaked at $29K in Q2 2021. 124 funds tracked by Wall St. Rank hold TCRT as of Q2 2022.

Xponance reported no remaining Alaunos Therapeutics position as of Q2 2022 after selling out during the quarter.
Xponance sold 68 Alaunos Therapeutics shares in Q2 2022, an estimated $7K.
Xponance first reported a position in Alaunos Therapeutics in Q2 2021 and held it in 2 quarters.
Xponance's Alaunos Therapeutics position peaked at $29K in Q2 2021.
124 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2022.

Based on Xponance's 13F filing for Q2 2022, filed 2 Aug 2022.